Roberto Iacone, Alentis CEO

Swiss-based up­start march­es to­ward the clin­ic with a unique ap­proach to fi­bro­sis treat­ment

For more than 10 years, Thomas Baumert has been care­ful­ly study­ing a pro­tein called Claudin-1 (CLDN1) for its role in fi­bro­sis. Now, hot off a $67 mil­lion raise, he’s rac­ing to the clin­ic with a mon­o­clon­al an­ti­body he hopes can re­verse kid­ney and liv­er dis­ease.

Alen­tis Ther­a­peu­tics, a biotech cross-bred in France and Switzer­land, un­veiled a Se­ries B round ear­ly Tues­day morn­ing that it will use to ad­vance its lead can­di­date ALE.F02 in­to the clin­ic at the end of this year. The com­pa­ny launched in 2019 with a $13.2 mil­lion round led by two Swiss VC funds, Bio­Med­Part­ners and BB Pure­os Bioven­tures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.